COO

Business Context and Reporting Period

Company: The Cooper Companies, Inc. (COO)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended January 31, 2025 (Fiscal Q1 2025)
Business Overview: The Company operates through two primary segments: CooperVision (contact lenses) and CooperSurgical (fertility and women's health care products). The Company is a large accelerated filer with 199,981,183 shares of Common Stock outstanding as of March 3, 2025.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 3.6% year-over-year, driven by growth in both segments. CooperVision sales rose 4.0% (Toric/multifocal +7%, Sphere +1%), while CooperSurgical sales rose 2.7% (Office/surgical +4%, Fertility +1%). Growth was partially offset by unfavorable foreign exchange impacts of approximately $18.0 million combined.
• Profitability: Operating income increased 19.0% to $182.0 million. CooperVision operating income grew 19.0% to $183.9 million, while CooperSurgical operating income declined 16.0% to $20.2 million due to higher amortization expenses from recent acquisitions.
• Expenses: Selling, general, and administrative (SG&A) expenses increased slightly to $387.9 million. Corporate SG&A decreased 14% due to lower share-based compensation. R&D expenses increased 3% to $40.7 million, primarily driven by CooperVision's myopia management programs.
• Interest Expense: Decreased 13% to $26.0 million due to lower interest rates and reduced debt balances.
• Cash Flow: Operating cash flow improved significantly to $190.6 million from $122.7 million. Investing cash outflows decreased to $96.8 million (from $324.1 million) as the prior year included a $200 million payment for the Cook Medical acquisition.

Guidance, Outlook, Risks, and Unusual Items

• Outlook: Management remains optimistic about long-term prospects in contact lens and general healthcare markets. The Company expects continued growth in single-use silicone hydrogel products and myopia management solutions.
• Acquisitions: Recent acquisitions include obp Surgical (August 2024, $100 million) and a fertility company (June 2024, $33.5 million). The Company also made a $47.1 million installment payment related to the Cook Medical acquisition in Q1 2025.
• Material Weakness in Internal Controls: The Company disclosed that its disclosure controls and procedures were not effective as of January 31, 2025, due to a material weakness in IT general controls within the CooperSurgical segment (U.S. operations). This relates to ERP implementation, personnel training, and change management. Remediation efforts are underway.
• Dividends: The Board decided in December 2023 to end the declaration of semiannual dividends.
• Share Repurchases: No shares were repurchased in Q1 2025. $256.4 million remains authorized under the current program.
• Risks: Key risks include foreign currency fluctuations, global economic conditions, supply chain disruptions, regulatory changes (e.g., EU MDR/IVDR), and cybersecurity threats.

Investor Verification Checklist

• Internal Control Remediation: Verify the progress and timeline for remediation of the material weakness in IT general controls at CooperSurgical.
• Foreign Exchange Impact: Monitor the sensitivity of earnings to currency fluctuations, which negatively impacted sales by ~$18 million in Q1.
• Amortization Pressure: Assess the impact of increased amortization from recent acquisitions on CooperSurgical's operating margins.
• Debt Covenants: Confirm continued compliance with the 2024 Credit Agreement covenants (Total Leverage Ratio and Interest Coverage Ratio).
• Product Mix Shift: Track the growth rate of single-use contact lenses versus frequent replacement products to validate the strategic shift.